China
# |
Name |
Net Income Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
400.15%
|
Dec. 31, 2023 | USD 0.36 | 6.46% |
|
China |
|
2 |
64.77%
|
Dec. 31, 2023 | USD 23.99 | 3.90% |
|
China |
|
3 |
59.30%
|
Sept. 30, 2023 | USD 2.00 | 0.50% |
|
China |
|
4 |
46.16%
|
Dec. 31, 2023 | USD 2.82 | 2.48% |
|
China |
|
5 |
44.84%
|
Dec. 31, 2023 | USD 4.94 | 3.02% |
|
China |
|
6 |
44.81%
|
Dec. 31, 2023 | USD 7.28 | 2.32% |
|
China |
|
7 |
42.44%
|
Dec. 31, 2023 | USD 3.27 | 2.18% |
|
China |
|
8 |
42.08%
|
Dec. 31, 2023 | USD 8.51 | 2.10% |
|
China |
|
9 |
41.90%
|
Dec. 31, 2023 | USD 15.35 | 4.46% |
|
China |
|
10 |
41.19%
|
Dec. 31, 2023 | USD 6.64 | 6.03% |
|
China |
|
11 |
40.92%
|
Dec. 31, 2023 | USD 1.04 | 1.87% |
|
China |
|
12 |
39.62%
|
Dec. 31, 2023 | USD 7.16 | 2.79% |
|
China |
|
13 |
37.97%
|
Dec. 31, 2023 | USD 1.05 | 3.24% |
|
China |
|
14 |
37.21%
|
Dec. 31, 2023 | USD 1.78 | 1.80% |
|
China |
|
15 |
36.57%
|
Dec. 31, 2023 | USD 2.64 | 3.21% |
|
China |
|
16 |
36.12%
|
Dec. 31, 2023 | USD 2.80 | 1.19% |
|
China |
|
17 |
35.68%
|
Dec. 31, 2023 | USD 2.46 | 5.25% |
|
China |
|
18 |
33.09%
|
Dec. 31, 2023 | USD 0.92 | 3.55% |
|
China |
|
19 |
32.28%
|
Dec. 31, 2023 | USD 7.13 | 3.78% |
|
China |
|
20 |
31.92%
|
Dec. 31, 2023 | USD 8.73 | 8.10% |
|
China |
|
21 |
31.24%
|
Dec. 31, 2023 | USD 1.84 | 3.23% |
|
China |
|
22 |
31.12%
|
Dec. 31, 2023 | USD 12.91 | 2.15% |
|
China |
|
23 |
30.07%
|
Dec. 31, 2023 | USD 1.77 | 3.28% |
|
China |
|
24 |
29.56%
|
Dec. 31, 2023 | USD 1.14 | 2.84% |
|
China |
|
25 |
29.05%
|
Dec. 31, 2023 | USD 2.89 | 3.83% |
|
China |
|
26 |
28.99%
|
Dec. 31, 2023 | USD 10.09 | 5.71% |
|
China |
|
27 |
28.12%
|
Dec. 31, 2023 | USD 5.09 | 2.06% |
|
China |
|
28 |
27.74%
|
Dec. 31, 2023 | USD 2.17 | 2.25% |
|
China |
|
29 |
27.65%
|
Dec. 31, 2023 | USD 3.24 | 2.11% |
|
China |
|
30 |
27.42%
|
Dec. 31, 2023 | USD 2.61 | 3.57% |
|
China |
|
31 |
27.42%
|
Dec. 31, 2023 | USD 3.72 | 2.09% |
|
China |
|
32 |
27.40%
|
Dec. 31, 2023 | USD 5.54 | 1.35% |
|
China |
|
33 |
26.45%
|
Dec. 31, 2023 | USD 9.77 | 0.05% |
|
China |
|
34 |
26.40%
|
Dec. 31, 2023 | USD 2.60 | 1.18% |
|
China |
|
35 |
26.12%
|
Dec. 31, 2023 | USD 0.90 | 3.77% |
|
China |
|
36 |
25.58%
|
Dec. 31, 2023 | USD 0.37 | 3.48% |
|
China |
|
37 |
25.55%
|
Dec. 31, 2023 | USD 4.89 | 2.67% |
|
China |
|
38 |
25.47%
|
Dec. 31, 2023 | USD 0.34 | -0.77% |
|
China |
|
39 |
25.06%
|
Dec. 31, 2023 | USD 2.96 | 2.80% |
|
China |
|
40 |
24.77%
|
Dec. 31, 2023 | USD 2.09 | 2.89% |
|
China |
|
41 |
24.41%
|
Dec. 31, 2023 | USD 8.44 | 1.77% |
|
China |
|
42 |
24.11%
|
Dec. 31, 2023 | USD 4.49 | 1.42% |
|
China |
|
43 |
23.95%
|
Dec. 31, 2023 | USD 2.37 | 1.89% |
|
China |
|
44 |
23.93%
|
Dec. 31, 2023 | USD 8.86 | 3.31% |
|
China |
|
45 |
23.81%
|
Dec. 31, 2023 | USD 6.95 | 4.11% |
|
China |
|
46 |
23.80%
|
Dec. 31, 2023 | USD 1.76 | 3.79% |
|
China |
|
47 |
23.17%
|
Dec. 31, 2023 | USD 3.73 | 3.49% |
|
China |
|
48 |
22.78%
|
Dec. 31, 2023 | USD 9.47 | 1.45% |
|
China |
|
49 |
22.71%
|
Dec. 31, 2023 | USD 4.00 | 1.74% |
|
China |
|
50 |
22.40%
|
Dec. 31, 2023 | USD 3.74 | 2.82% |
|
China |
The Biotechnology company in China with the highest Net Income Margin is Shandong Oriental Ocean Sci-Tech Co., Ltd. (Shenzhen Stock Exchange: 002086.SZ) at 400.15%.
The Biotechnology company in China with the lowest Net Income Margin is ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKSE: 1541.HK) at -98,305.44%.
The top 10 Biotechnology companies in China by Net Income Margin are Shandong Oriental Ocean Sci-Tech Co., Ltd., Imeik Technology Development Co.,Ltd., Origin Agritech Limited, Yantai Zhenghai Biotechnology Co., Ltd., Shanghai Yizhong Pharmaceutical Co., Ltd., Akeso, Inc., Beijing Succeeder Technology Inc., Shenzhen New Industries Biomedical Engineering Co., Ltd., Shanghai MicroPort Endovascular MedTech Co., Ltd. and Giant Biogene Holding Co., Ltd..
The bottom 10 Biotechnology companies in China by Net Income Margin are ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Abbisko Cayman Limited, Jiangsu Recbio Technology Co., Ltd., Wuhan YZY Biopharma Co Ltd, Cutia Therapeutics, Mabwell (Shanghai) Bioscience Co., Ltd., Jacobio Pharmaceuticals Group Co., Ltd., JW (Cayman) Therapeutics Co. Ltd, CanSino Biologics Inc. and Ascentage Pharma Group International.